Zai Lab Ltd ( (HK:9688) ) has provided an announcement.
Zai Lab Limited announced a significant increase in revenues for the fourth quarter and full-year 2024, driven by the strong performance of its VYVGART franchise and other products. The company reported a 66% year-over-year revenue growth for the fourth quarter and a 50% increase for the full year, with expectations of continued growth in 2025. Zai Lab highlighted advancements in its pipeline, including the acceptance of KarXT’s New Drug Application in China and promising data from its global asset ZL-1310 for small cell lung cancer. The company aims to achieve substantial revenue growth and profitability by 2028, supported by its robust cash position and strategic investments in high-impact growth opportunities.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company focused on developing and commercializing innovative therapies, particularly in the fields of oncology, autoimmune disorders, and infectious diseases. The company is known for its strong pipeline of products and its market focus on China and global markets.
YTD Price Performance: 31.15%
Average Trading Volume: 422
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €3.68B
For a thorough assessment of 9688 stock, go to TipRanks’ Stock Analysis page.